SCHEMBL6500067

SCHEMBL6500067

[O]CC#Cc1ccncc1

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
FFAR1 O14842 1/20 0.43
HDAC8 Q9BY41 2/20 0.42
GRM5 P41594 2/20 0.37
DRD2 P14416 1/20 0.36
DRD4 P21917 1/20 0.36
DRD3 P35462 1/20 0.36
CYP2C9 P11712 4/20 0.35
CYP2C19 P33261 4/20 0.35
CYP3A4 P08684 3/20 0.35
CYP2A6 P11509 3/20 0.35
CYP2B6 P20813 3/20 0.35
CYP2E1 P05181 2/20 0.35
CYP2D6 P10635 2/20 0.35
CYP1A2 P05177 2/20 0.34
CYP2C8 P10632 1/20 0.34
PIK3CD O00329 1/20 0.34
PIK3CA P42336 1/20 0.34
MTOR P42345 1/20 0.34
PIK3CG P48736 1/20 0.34
PDK1 Q15118 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13598887 0.77 MAPK14 (0.42) FFAR1HDAC8DRD2DRD4DRD3
SCHEMBL4419011 0.76 HDAC8 (0.42) FFAR1HDAC8GRM5DRD2DRD4
SCHEMBL21623412 0.76 HDAC8 (0.42) FFAR1HDAC8GRM5DRD2DRD4
SCHEMBL14985138 0.76 HDAC8 (0.42) FFAR1HDAC8GRM5DRD2DRD4
SCHEMBL6500070 0.76 MELK (0.55) FFAR1HDAC8GRM5DRD2DRD4
SCHEMBL28417116 0.76 HDAC8 (0.42) FFAR1HDAC8GRM5DRD2DRD4
SCHEMBL4072436 0.76 CYP2C19 (0.60) HDAC8CYP2C9CYP2C19CYP3A4CYP2A6
SCHEMBL21623413 0.76 HDAC8 (0.42) FFAR1HDAC8GRM5DRD2DRD4
SCHEMBL1820120 0.76 HDAC8 (0.58) FFAR1HDAC8GRM5CYP2D6PIK3CD
SCHEMBL96139 0.75 CYP1A2 (0.58) FFAR1CYP2C9CYP2C19CYP3A4CYP1A2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6884806-B2 Bicyclic lactam derivatives as inhibitors of matrix metalloproteinases and/or TNF-α converting enzyme (TACE) BRISTOL-MYERS SQUIBB COMPANY (US) 2005-04-26 US disclosed
US-6495565-B2 FOR THERAPY OF ACUTE INFECTION, ACUTE PHASE RESPONSE, AGE RELATED MACULAR DEGENERATION, ALCOHOLISM, ANOREXIA, ASTHMA, AUTOIMMUNE DISEASE, AUTOIMMUNE HEPATITIS, BECHET'S DISEASE, CACHEXIA, CALCIUM PYROPHOSPHATE DIHYDRTATE DEPOSITION BRISTOL-MYERS SQUIBB PHARMA COMPANY 2002-12-17 US disclosed